MI Cancer Seek
Caris Life Sciences · Decision date Jul 2, 2026
What did the FDA decide?
FDA records P240010/S010 as a supplement to PMA P240010, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 2, 2026.
FDA approval order statement
update to QC specification limits
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Medical Genetics
- Decision date
- Jul 2, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P240010/S010
- Regulatory pathway
- PMA supplement
- Applicant
- Caris Life Sciences
- Product code
- PQP
- Decision code
- OK30
- Decision date
- Jul 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Caris Life Sciences
- Product code
- PQP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240010. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240010 · Original PMA
MI Cancer Seek
P240010/S009 · Related supplement
MI Cancer Seek
P240010/S010 received
Application receipt date recorded by FDA.
P240010/S010 · FDA decision
30-Day Notice
P240010/S007 · Related supplement
MI Cancer Seek
Timeline entries are records held by MedtechLedger for P240010. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240010
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MI Cancer SeekP240010 | Caris Life Sciences | PMA approval | Nov 5, 2024 | FDA |
MI Cancer SeekP240010/S009 | Caris Life Sciences | PMA supplement | May 28, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
FoundationOne CDxP170019/S069 | Foundation Medicine, Inc. | PMA supplement | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Caris Life Sciences
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4610 S. 44th Pl., Phoenix, AZ, 85040
Sources and methodology
- Original FDA record: P240010/S010
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



